These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33934680)

  • 21. Statin exposure during pregnancy promotes neuromuscular junction alterations in postpartum Wistar rats.
    Muller KS; Tibúrcio FC; de Barros JWF; Matsumura CY; Matheus SMM
    Muscle Nerve; 2023 Jun; 67(6):537-547. PubMed ID: 36975763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosuvastatin: characterization of induced myopathy in the rat.
    Westwood FR; Scott RC; Marsden AM; Bigley A; Randall K
    Toxicol Pathol; 2008 Feb; 36(2):345-52. PubMed ID: 18362199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ascorbic acid supplementation ameliorates testicular hormonal signaling, sperm production and oxidative stress in male rats exposed to rosuvastatin during pre-puberty.
    Leite GAA; de Barros JWF; Martins ADC; Anselmo-Franci JA; Barbosa F; Kempinas WG
    J Appl Toxicol; 2019 Feb; 39(2):305-321. PubMed ID: 30240002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents.
    Capra V; Rovati GE
    Pulm Pharmacol Ther; 2014 Feb; 27(1):10-6. PubMed ID: 23806820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin.
    Berber AA; Celik M; Aksoy H
    Drug Chem Toxicol; 2014 Jul; 37(3):316-21. PubMed ID: 24245812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statins alleviate experimental nerve injury-induced neuropathic pain.
    Shi XQ; Lim TKY; Lee S; Zhao YQ; Zhang J
    Pain; 2011 May; 152(5):1033-1043. PubMed ID: 21414721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacologic characteristics of rosuvastatin, a new HMG-CoA reductase inhibitor].
    Bousquet P; Gayet JL
    Therapie; 2003; 58(2):113-21. PubMed ID: 12942850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensive Statin Therapy Compromises the Adiponectin-AdipoR Pathway in the Human Monocyte-Macrophage Lineage.
    Gasbarrino K; Hafiane A; Zheng H; Daskalopoulou SS
    Stroke; 2019 Dec; 50(12):3609-3617. PubMed ID: 31648632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
    Singh S; Willig JH; Mugavero MJ; Crane PK; Harrington RD; Knopp RH; Kosel BW; Saag MS; Kitahata MM; Crane HM
    Clin Infect Dis; 2011 Feb; 52(3):387-95. PubMed ID: 21189273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative responses of three rat strains (DA/Han, Sprague-Dawley and Wistar) to treatment with environmental estrogens.
    Diel P; Schmidt S; Vollmer G; Janning P; Upmeier A; Michna H; Bolt HM; Degen GH
    Arch Toxicol; 2004 Apr; 78(4):183-93. PubMed ID: 14689164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reproductive outcomes in rat female offspring from male rats co-exposed to rosuvastatin and ascorbic acid during pre-puberty.
    Leite GAA; Figueiredo TM; Pacheco TL; Guerra MT; Anselmo-Franci JA; Kempinas WG
    J Toxicol Environ Health A; 2018; 81(17):873-892. PubMed ID: 30081759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
    Laufs U; Gertz K; Dirnagl U; Böhm M; Nickenig G; Endres M
    Brain Res; 2002 Jun; 942(1-2):23-30. PubMed ID: 12031849
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Rosuvastatin on the expression of the genes involved in cholesterol metabolism in rats: adaptive responses by extrahepatic tissues.
    Ahmadi Y; Haghjoo AG; Dastmalchi S; Nemati M; Bargahi N
    Gene; 2018 Jun; 661():45-50. PubMed ID: 29605604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
    Milner E; Ainsworth M; Gleaton M; Bookstaver D
    J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
    Cheng-Lai A
    Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosuvastatin: efficacy, safety and clinical effectiveness.
    Soran H; Durrington P
    Expert Opin Pharmacother; 2008 Aug; 9(12):2145-60. PubMed ID: 18671469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
    McKenney JM
    Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
    Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM
    Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
    Martin PD; Mitchell PD; Schneck DW
    Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.